Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHP465 in children and adolescents with ADHD
NCT02466425Phase 3Completed
- Sponsor
- Takeda
- Start
- Jun 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing SHP465 with Placebo (2 arms). Primary endpoint: Change From Baseline in Attention-Deficit Hyperactivity Disorder Rating Scale-IV Total Score at 4 weeks. Started Jun 2015; status: completed.
02
Drugs
SHP465 mixed amphetamine salts
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02466425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466425.